Edesa Biotech (EDSA) Peer Comparison

$4.78

$0.05 (1.02%)

As on 01-Sep-2026 12:31EDT

Market cap

$45 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

111.2

Div. Yield

0 %

Edit

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Market cap ($ Mln)	45	5,809	2,167	3,678	345
Revenue ($ Mln)	0	--	312	66	0
Net Profit ($ Mln)	-14.10	-409.20	314.11	-164.66	-37.54
Net Margin (%)	-27,695.45	--	100.84	-248.83	134,079.79
RoE (%)	-123.89	-44.86	52.52	-17.68	-79.49
Price to Earnings	--	--	7.14	--	--
Price-To-Book	111.16	4.83	3.57	4.48	9.49

Cashflow
Ratios

Cashflow ($ Mln)

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Cash From Operating Activities	-7.32	-279.12	135.66	-131.30	-29.06
Cash Flow from Investing Activities	--	218.00	-32.77	87.75	-2.19
Cash from Financing Activities	17.03	117.11	-106.11	14.08	43.88
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
ROCE (%)	-99.43	-51.11	51.61	-13.12	-67.28
ROE (%)	-123.89	-44.86	52.52	-17.68	-79.49
ROA (%)	-72.36	-27.75	42.65	-11.64	-60.11
EBIT Margin (%)	-28,293.86	--	54.20	-304.58	133,972.64
Net Margin (%)	-27,695.45	-4,612.13	100.84	-248.83	134,079.79
Cash Profit Margin (%)	-0.36	--	0.00	0.00	3.35

Growth Ratios

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Revenue Growth (%)	--	--	19.76	101.28	-100.20
EBIT Growth (%)	-145.57	3.41	151.91	23.59	-26.93
Net Profit Growth (%)	-138.24	-47.07	418.03	0.61	-26.91
EPS Growth (%)	-26.91	-34.29	434.98	2.53	-6.40
Book Value Growth (%)	-51.39	55.33	96.66	-13.08	12.47

Valuation Ratios

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Price / Earnings	-2.43	-10.27	7.70	-6.98	-11.41
Price / Book Value	1.40	6.11	3.81	1.06	6.66
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.94	-8.80	14.79	-4.24	-9.61
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.00	0.03	0.01	0.00
Current Ratio	2.76	21.02	5.42	12.77	6.72
Quick Ratio	2.76	21.02	4.97	12.63	6.72
Interest Coverage	--	--	17.75	-11.19	--

Operating Efficiency Ratios

	Edesa Biotech (EDSA)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Debtors to sales (%)	447.88	18.28	13.21	144.21	0.00
Asset Turnover	0.00	0.00	0.42	0.05	0.00
Receivable days	--	69.15	50.32	596.85	--
Inventory Days	--	--	474.76	40.15	--
Payable days	4,427.32	643.10	47.52	377.52	--
Cash Conversion Cycle	--	--	477.57	259.48	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly